BioAtla, Inc.

BCAB

BioAtla, Inc.

BCAB

Insider Sentiment (TTM):

Last Purchase:2023-12-26Last Sale:2021-12-02Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:14,146,665Shares Outstanding:1,501,649Institutional Ownership Pct.:N/A

Earnings Market Reaction:

Filing Date:2026-05-15Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX BIIB MRNA RVMD

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	2	7	8	18	32	49	57	62	81	111	141	169
Prepaid Expense And Other Assets Current	1	1	1	2	5	2	4	5	6	5	6	7
Assets Current	3	8	10	21	38	51	61	66	86	116	148	175
Property Plant And Equipment Net	0	0	0	0	0	1	1	1	1	2	2	2
Operating Lease Right Of Use Asset	5	6	6	6	0	1	1	1	1	1	2	2
Other Assets Noncurrent	0	0	0	0	-	0	0	0	0	0	0	0
Assets	9	14	16	27	38	52	62	69	89	120	151	180
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	19	16	17	16	15	14	18	16	18	27	34	32
Operating Lease Liability Current	2	1	1	1	1	1	1	2	2	2	2	2
Liabilities Current	21	22	18	17	16	15	19	17	19	28	36	34
Operating Lease Liability Noncurrent	5	5	5	5	-	0	0	0	0	1	1	2
Liabilities	46	50	47	44	38	38	39	37	39	49	57	55
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	515	509	505	503	502	500	494	492	489	487	484	481
Retained Earnings Accumulated Deficit	-552	-546	-536	-520	-501	-486	-471	-461	-439	-416	-389	-356
Stockholders Equity	-37	-36	-31	-17	1	14	23	31	50	71	95	125
Liabilities And Stockholders Equity	9	14	16	27	38	52	62	69	89	120	151	180
Accounts Payable Current And Noncurrent	-	-	0	-	-	-	2	-	-	-	-	-
Common Class B	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	350	350	350	350	350	350	350	350	350	350	350	350
Common Stock Shares Issued	2	2	2	2	1	1	1	1	1	1	1	1
Shares Outstanding	2	2	1	1	1	1	2	2	2	2	1	1

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-22.01%	-1.87%	-	-	-	-	-	-	-	-	-	-
2025	-13.89%	-19.16%	-25.26%	20.00%	76.05%	100.00%	24.85%	-19.09%	-59.24%	-39.50%	-54.16%	-54.60%
2024	-41.76%	-49.43%	-39.08%	20.41%	10.88%	35.37%	-24.32%	-71.26%	-77.48%	-13.14%	7.24%	8.85%
2023	-	-	-	-15.62%	-37.85%	-44.44%	0.57%	39.77%	17.05%	-30.07%	-5.98%	-47.18%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	0.15	0.37	0.54	1.24	2.35	3.52	3.11	3.81	4.49	4.11	4.14	5.21
Quick Ratio	0.09	0.32	0.46	1.10	2.02	3.37	2.90	3.53	4.19	3.93	3.97	5.01
Working Capital	-17.60M	-13.91M	-8.31M	4.01M	21.53M	36.69M	41.11M	49.03M	67.17M	88.06M	111.91M	141.65M
Leverage & Debt
Debt to Equity	-1.23	1.38	-1.51	-2.62	69.00	2.67	1.71	1.19	0.79	0.69	0.60	0.44
Debt Ratio	5.36	3.62	2.96	1.62	0.99	0.73	0.63	0.54	0.44	0.41	0.37	0.31
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-33.71	-39.52	-42.96	-39.67	-41.43	-47.06	-55.45	-71.04	-81.23	-84.66	-84.98	-80.02
Free Cash Flow Per Share TTM	-24.76	-31.96	-37.89	-34.88	-38.43	-48.52	-57.66	-72.90	-76.43	-71.32	-67.42	-65.31
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-18.20%	-14.57%	-20.91%	-43.08%	-48.11%	-43.48%	-34.06%	-10.28%	8.70%	15.95%	21.26%	17.14%
EPS Growth (1Y)	-18.64%	-16.03%	-22.53%	-44.15%	-49.00%	-44.41%	-34.75%	-11.22%	7.55%	-5.53%	-4.90%	-8.11%
Valuation Metrics
P/E TTM	-0.24	-0.72	-0.80	-0.50	-0.42	-0.63	-1.59	-0.96	-2.12	-1.45	-1.00	-1.87
P/B TTM	-0.32	1.18	-1.66	-1.77	47.37	3.07	5.65	3.21	5.08	2.54	1.31	1.75
Market Cap	12.09M	42.84M	51.82M	29.70M	25.91M	43.81M	129.84M	100.82M	252.47M	179.38M	124.11M	218.44M
Enterprise Value	10.13M	35.72M	43.50M	11.50M	-6.45M	-5.23M	73.32M	39.15M	171.84M	67.91M	-17.17M	49.74M
Calculated Values
Free Cash Flow TTM	-37.18M	-48.20M	-57.07M	-52.32M	-57.40M	-71.94M	-85.08M	-107.29M	-112.19M	-104.02M	-98.44M	-95.11M
Net Debt	-1.96M	-7.12M	-8.32M	-18.21M	-32.36M	-49.05M	-56.52M	-61.66M	-80.63M	-111.47M	-141.28M	-168.69M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2023-12-26Purchase

Owner: Mcbrinn, Sylvia

Title: -

Shares: 4,000

Price/Share: $2.33

Value: $9,320.00

Shares Owned: 15,125

Relationship: Director

Ownership: Direct

2023-12-20Purchase

Owner: Short, Jay M Phd

Title: Chief Executive Officer

Shares: 50,000

Price/Share: $2.14

Value: $107,000.00

Shares Owned: 1,439,283

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2023-12-19Purchase

Owner: Vasquez, Christian

Title: See Remarks

Shares: 7,495

Price/Share: $2.04

Value: $15,289.80

Shares Owned: 115,659

Relationship: Officer

Ownership: Direct

2023-12-19Purchase

Owner: Steinman, Lawrence

Title: -

Shares: 20,000

Price/Share: $2.05

Value: $41,000.00

Shares Owned: 38,459

Relationship: Director

Ownership: Direct

2023-09-08Purchase

Owner: Mcbrinn, Sylvia

Title: -

Shares: 2,000

Price/Share: $2.54

Value: $5,080.00

Shares Owned: 11,125

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2023-12-26	Mcbrinn, Sylvia	Director	-	Direct	Purchase	4,000	2.33	$9,320.00	15,125	4
2023-12-20	Short, Jay M Phd	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Purchase	50,000	2.14	$107,000.00	1,439,283	4
2023-12-19	Vasquez, Christian	Officer	See Remarks	Direct	Purchase	7,495	2.04	$15,289.80	115,659	4
2023-12-19	Steinman, Lawrence	Director	-	Direct	Purchase	20,000	2.05	$41,000.00	38,459	4
2023-09-08	Mcbrinn, Sylvia	Director	-	Direct	Purchase	2,000	2.54	$5,080.00	11,125	4
2023-03-29	Short, Jay M Phd	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Purchase	40,800	2.47	$100,776.00	1,412,387	4
2023-03-28	Mcbrinn, Sylvia	Director	-	Direct	Purchase	4,000	2.35	$9,400.00	19,125	4
2023-03-28	Vasquez, Christian	Officer	See Remarks	Direct	Purchase	20,000	2.40	$48,000.00	102,709	4
2022-12-19	Mcbrinn, Sylvia	Director	-	Direct	Purchase	3,700	8.33	$30,821.00	9,125	4
2022-11-22	Mcbrinn, Sylvia	Director	-	Direct	Purchase	2,000	8.27	$16,540.00	5,425	4
2022-09-13	Mcbrinn, Sylvia	Director	-	Direct	Purchase	1,000	8.20	$8,200.00	3,000	4
2022-08-12	Short, Jay M Phd	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Purchase	26,350	7.84	$206,584.00	1,396,556	4
2022-06-22	Short, Jay M Phd	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Purchase	40,308	2.91	$117,296.28	1,375,982	4
2022-06-09	Vasquez, Christian	Officer	See Remarks	Direct	Purchase	10,000	2.97	$29,700.00	74,525	4
2021-12-02	Waldron, Richard A	Officer	Chief Financial Officer	Direct	Sale	1,434	22.10	$31,691.40	134,469	4
2021-12-02	Vasquez, Christian	Officer	See Remarks	Direct	Sale	200	22.10	$4,420.00	25,259	4
2021-12-02	Sievers, Eric	Officer	Chief Medical Officer	Direct	Sale	820	22.10	$18,122.00	91,506	4
2021-12-02	Smith, Scott Andrew	Director,Officer	President	Direct	Sale	2,984	22.10	$65,946.40	345,656	4
2021-12-02	Short, Jay M Phd	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Sale	4,811	22.10	$106,323.10	1,320,811	4
2021-11-29	Sievers, Eric	Officer	Chief Medical Officer	Direct	Sale	110	23.89	$2,627.90	92,630	4
2021-11-29	Vasquez, Christian	Officer	See Remarks	Direct	Sale	642	23.89	$15,337.38	27,238	4
2021-11-29	Smith, Scott Andrew	Director,Officer	President	Direct	Sale	399	23.89	$9,532.11	349,746	4
2021-11-29	Waldron, Richard A	Officer	Chief Financial Officer	Direct	Sale	4,599	23.89	$109,870.11	148,659	4
2021-11-29	Short, Jay M Phd	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Sale	15,435	23.89	$368,742.15	1,368,433	4
2021-11-24	Waldron, Richard A	Officer	Chief Financial Officer	Direct	Sale	3,937	24.94	$98,188.78	153,258	4
2021-11-24	Sievers, Eric	Officer	Chief Medical Officer	Direct	Sale	129	24.94	$3,217.26	92,740	4
2021-11-24	Smith, Scott Andrew	Director,Officer	President	Direct	Sale	466	24.94	$11,622.04	350,145	4
2021-11-24	Vasquez, Christian	Officer	See Remarks	Direct	Sale	750	24.94	$18,705.00	27,880	4
2021-11-24	Short, Jay M Phd	Director,Officer,TenPercentOwner	Chief Executive Officer	Direct	Sale	17,022	24.94	$424,528.68	1,383,868	4
2021-11-02	Steinman, Lawrence	Director	-	Direct	Sale	450	30.00	$13,500.00	18,459	4
2021-10-01	Smith, Scott Andrew	Director,Officer	President	Direct	Sale	2,994	30.18	$90,358.92	351,725	4
2021-10-01	Sievers, Eric	Officer	Chief Medical Officer	Direct	Sale	592	30.39	$17,990.88	93,174	4
2021-09-15	Steinman, Lawrence	Director	-	Direct	Sale	450	36.82	$16,569.00	18,909	4
2021-08-26	Sievers, Eric	Officer	Chief Medical Officer	Direct	Sale	6,883	39.59	$272,497.97	93,766	4
2021-08-26	Smith, Scott Andrew	Director,Officer	President	Direct	Sale	33,244	40.26	$1,338,403.44	354,719	4
2021-08-24	Levy, Guy	Director	-	Indirect	Sale	546,709	39.65	$21,677,011.85	217,358	4
2021-08-24	Short, Jay M Phd	Director,Officer,TenPercentOwner	Chief Executive Officer	Indirect	Sale	4,533	41.60	$188,572.80	793,547	4
2021-08-16	Steinman, Lawrence	Director	-	Direct	Sale	450	40.60	$18,270.00	19,359	4
2021-07-15	Steinman, Lawrence	Director	-	Direct	Sale	450	38.29	$17,230.50	19,809	4
2021-06-21	Short, Jay M Phd	Director,Officer,TenPercentOwner	Chief Executive Officer	Indirect	Sale	55,000	39.22	$2,157,100.00	790,333	4
2021-06-17	Levy, Guy	Director	-	Indirect	Sale	400,000	39.16	$15,664,000.00	270,553	4
2021-06-16	Short, Jay M Phd	Director,Officer,TenPercentOwner	Chief Executive Officer	Indirect	Sale	35,417	39.70	$1,406,054.90	864,602	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

Inst. Shares: 14,146,665

Shares Outstanding: 1,501,649

2025-12-31

Inst. Shares: 12,311,630

Shares Outstanding: 1,508,409

2025-09-30

Inst. Shares: 12,247,787

Shares Outstanding: 1,506,291

2025-06-30

Inst. Shares: 11,554,076

Shares Outstanding: 1,500,113

2025-03-31

Inst. Shares: 11,655,516

Shares Outstanding: 1,493,569

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	14,146,665	1,501,649	-
2025-12-31	12,311,630	1,508,409	-
2025-09-30	12,247,787	1,506,291	-
2025-06-30	11,554,076	1,500,113	-
2025-03-31	11,655,516	1,493,569	-
2024-12-31	23,468,478	1,482,703	-
2024-09-30	16,788,581	1,475,453	-
2024-06-30	21,958,309	1,471,761	-
2024-03-31	23,438,483	1,467,871	-
2023-12-31	25,704,103	1,458,412	-
2023-09-30	28,856,489	1,460,138	-
2023-06-30	29,895,892	1,456,240	-
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

BioAtla, Inc. (BCAB) — SEC Financial Statements & Analysis

BioAtla, Inc. (BCAB) is a biological products, (no diagnostic substances) company, incorporated in DE. BioAtla, Inc. trades on Nasdaq as: BCAB. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), BioAtla, Inc. reported a Debt-to-Equity ratio of -1.23x, a Price-to-Book (P/B) ratio of -0.32 (TTM), at a market cap of $12.09M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: -1.23x
P/B TTM: -0.32
Market Cap: $12.09M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is BioAtla, Inc. in?

BioAtla, Inc. (BCAB) operates in the Biological Products, (No Diagnostic Substances) industry.

What is BCAB's market cap?

BioAtla, Inc. (BCAB) has a market capitalization of $12.09M as of 2026-03-31.

What exchange does BCAB trade on?

BioAtla, Inc. (BCAB) trades on the Nasdaq.

Where is BioAtla, Inc. incorporated?

BioAtla, Inc. is incorporated in DE.

BioAtla, Inc. (BCAB) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.